Table 3 Clinical characteristics at baseline, at month 3 (M3) and at month 6 (M6)

N

162

162

134

MMD [mean ± SD]

18.0 ± 7.5

9.8 ± 9.0

7.3 ± 7.6

MHD [mean ± SD]

23.3 ± 6.9

15.0 ± 10.5

12.5 ± 10.0

Intensities [mean ± SD]

n = 113/162

n = 114/162

n = 96/134

 Mild days/month

4.3 ± 6.3

6.1 ± 8.4

6.0 ± 8.4

 Moderate days/month

8.3 ± 7.5

4.9 ± 6.2

3.4 ± 4.3

 Severe days/month

9.3 ± 8.1

2.9 ± 5.4

2.2 ± 4.1

MAMI [mean ± SD]

18.9 ± 8.0

n = 153/162

11.1 ± 9.3

n = 147/162

9.4 ± 8.9

n = 129/134

Medication overuse [n (%)]

107 (66.5)

57 (35.2)

37 (27.8)

HIT-6 [mean ± SD]

65.9 ± 7.8

n = 141/162

57.1 ± 11.9

n = 135/162

55.2 ± 11.1

n = 114/134

MIDAS [mean ± SD]

80.3 ± 71.3

n = 129/162

45.2 ± 62.0

n = 121/162

34.4 ± 48.1

n = 101/134

PGIC [mean ± SD]

-

3.78 ± 2.0

n = 130/162

4.13 ± 2.1

n = 110/134

Concomitant oral treatment [n (%)]

102 (63.0)

89 (55.3)

64 (47.8)

Concomitant onabotulinum toxin A [n (%)]

31 (19.1)

25 (15.5)

18 (13.4)